Therefore, GSN is considered a promising biomarker in the early stage of tumor invasion and metastasis and might become an effective molecular target to identify and screen tumor metastasis through the lymphatic system (Wang et al., 2014; Huang et al., 2022). The gene discussed is GSN; the disease is neoplasm.